218 related articles for article (PubMed ID: 21314962)
1. Phase i study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: the PROMETHEUS-01 trial.
Combs SE; Habermehl D; Ganten T; Schmidt J; Edler L; Burkholder I; Jäkel O; Haberer T; Debus J
BMC Cancer; 2011 Feb; 11():67. PubMed ID: 21314962
[TBL] [Abstract][Full Text] [Related]
2. Randomised phase I/II study to evaluate carbon ion radiotherapy versus fractionated stereotactic radiotherapy in patients with recurrent or progressive gliomas: the CINDERELLA trial.
Combs SE; Burkholder I; Edler L; Rieken S; Habermehl D; Jäkel O; Haberer T; Haselmann R; Unterberg A; Wick W; Debus J
BMC Cancer; 2010 Oct; 10():533. PubMed ID: 20925951
[TBL] [Abstract][Full Text] [Related]
3. Hypofractionated carbon ion therapy delivered with scanned ion beams for patients with hepatocellular carcinoma - feasibility and clinical response.
Habermehl D; Debus J; Ganten T; Ganten MK; Bauer J; Brecht IC; Brons S; Haberer T; Haertig M; Jäkel O; Parodi K; Welzel T; Combs SE
Radiat Oncol; 2013 Mar; 8():59. PubMed ID: 23497349
[TBL] [Abstract][Full Text] [Related]
4. Phase I study evaluating the treatment of patients with locally advanced pancreatic cancer with carbon ion radiotherapy: the PHOENIX-01 trial.
Combs SE; Habermehl D; Kieser M; Dreher C; Werner J; Haselmann R; Jäkel O; Jäger D; Büchler MW; Debus J
BMC Cancer; 2013 Sep; 13():419. PubMed ID: 24034562
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II trial evaluating carbon ion radiotherapy for the treatment of recurrent rectal cancer: the PANDORA-01 trial.
Combs SE; Kieser M; Habermehl D; Weitz J; Jäger D; Fossati P; Orrechia R; Engenhart-Cabillic R; Pötter R; Dosanjh M; Jäkel O; Büchler MW; Debus J
BMC Cancer; 2012 Apr; 12():137. PubMed ID: 22472035
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial.
Combs SE; Kieser M; Rieken S; Habermehl D; Jäkel O; Haberer T; Nikoghosyan A; Haselmann R; Unterberg A; Wick W; Debus J
BMC Cancer; 2010 Sep; 10():478. PubMed ID: 20819220
[TBL] [Abstract][Full Text] [Related]
7. Treatment of patients with atypical meningiomas Simpson grade 4 and 5 with a carbon ion boost in combination with postoperative photon radiotherapy: the MARCIE trial.
Combs SE; Edler L; Burkholder I; Rieken S; Habermehl D; Jäkel O; Haberer T; Unterberg A; Wick W; Debus J; Haselmann R
BMC Cancer; 2010 Nov; 10():615. PubMed ID: 21062428
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II Trial Evaluating Carbon Ion Radiotherapy for Salvaging Treatment of Locally Recurrent Nasopharyngeal Carcinoma.
Kong L; Hu J; Guan X; Gao J; Lu R; Lu JJ
J Cancer; 2016; 7(7):774-83. PubMed ID: 27162535
[TBL] [Abstract][Full Text] [Related]
9. Carbon ion radiotherapy of hepatocellular carcinoma provides excellent local control: The prospective phase I PROMETHEUS trial.
Hoegen-Saßmannshausen P; Naumann P; Hoffmeister-Wittmann P; Ben Harrabi S; Seidensaal K; Weykamp F; Mielke T; Ellerbrock M; Habermehl D; Springfeld C; Dill MT; Longerich T; Schirmacher P; Mehrabi A; Chang DH; Hörner-Rieber J; Jäkel O; Haberer T; Combs SE; Debus J; Herfarth K; Liermann J
JHEP Rep; 2024 Jun; 6(6):101063. PubMed ID: 38737600
[TBL] [Abstract][Full Text] [Related]
10. Clinical impact of Hypofractionated carbon ion radiotherapy on locally advanced hepatocellular carcinoma.
Shiba S; Shibuya K; Okamoto M; Okazaki S; Komatsu S; Kubota Y; Nakano T; Ohno T
Radiat Oncol; 2020 Aug; 15(1):195. PubMed ID: 32795340
[TBL] [Abstract][Full Text] [Related]
11. Charged-particle therapy for hepatocellular carcinoma.
Skinner HD; Hong TS; Krishnan S
Semin Radiat Oncol; 2011 Oct; 21(4):278-86. PubMed ID: 21939857
[TBL] [Abstract][Full Text] [Related]
12. Phase I dose escalation study of helical intensity-modulated radiotherapy-based stereotactic body radiotherapy for hepatocellular carcinoma.
Kim JW; Seong J; Lee IJ; Woo JY; Han KH
Oncotarget; 2016 Jun; 7(26):40756-40766. PubMed ID: 27213593
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II trial of hypofractionated proton versus carbon ion radiation therapy in patients with sacrococcygeal chordoma-the ISAC trial protocol.
Uhl M; Edler L; Jensen AD; Habl G; Oelmann J; Röder F; Jäckel O; Debus J; Herfarth K
Radiat Oncol; 2014 Apr; 9():100. PubMed ID: 24774721
[TBL] [Abstract][Full Text] [Related]
14. Progressive hypofractionated carbon-ion radiotherapy for hepatocellular carcinoma: Combined analyses of 2 prospective trials.
Kasuya G; Kato H; Yasuda S; Tsuji H; Yamada S; Haruyama Y; Kobashi G; Ebner DK; Okada NN; Makishima H; Miyazaki M; Kamada T; Tsujii H;
Cancer; 2017 Oct; 123(20):3955-3965. PubMed ID: 28662297
[TBL] [Abstract][Full Text] [Related]
15. The relative biological effectiveness for carbon and oxygen ion beams using the raster-scanning technique in hepatocellular carcinoma cell lines.
Habermehl D; Ilicic K; Dehne S; Rieken S; Orschiedt L; Brons S; Haberer T; Weber KJ; Debus J; Combs SE
PLoS One; 2014; 9(12):e113591. PubMed ID: 25460352
[TBL] [Abstract][Full Text] [Related]
16. A feasibility study of high-dose hypofractionated carbon ion radiation therapy using four fractions for localized hepatocellular carcinoma measuring 3 cm or larger.
Shibuya K; Ohno T; Katoh H; Okamoto M; Shiba S; Koyama Y; Kakizaki S; Shirabe K; Nakano T
Radiother Oncol; 2019 Mar; 132():230-235. PubMed ID: 30366726
[TBL] [Abstract][Full Text] [Related]
17. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.
Gandhi M; Choo SP; Thng CH; Tan SB; Low AS; Cheow PC; Goh AS; Tay KH; Lo RH; Goh BK; Wong JS; Ng DC; Soo KC; Liew WM; Chow PK;
BMC Cancer; 2016 Nov; 16(1):856. PubMed ID: 27821083
[TBL] [Abstract][Full Text] [Related]
18. Carbon Ion Radiotherapy in the Treatment of Hepatocellular Carcinoma.
Byun HK; Kim C; Seong J
Clin Mol Hepatol; 2023 Oct; 29(4):945-957. PubMed ID: 37583055
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
[TBL] [Abstract][Full Text] [Related]
20. Results of the first prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis.
Kato H; Tsujii H; Miyamoto T; Mizoe JE; Kamada T; Tsuji H; Yamada S; Kandatsu S; Yoshikawa K; Obata T; Ezawa H; Morita S; Tomizawa M; Morimoto N; Fujita J; Ohto M;
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1468-76. PubMed ID: 15275734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
